Podcast

Juggling a Career and Navigating Cancer Treatment

This week on the “CURE® Talks Cancer” podcast, we spoke with Evofem Biosciences founder and CEO Saundra Pelletier about what it was like to go through the shock of receiving a cancer diagnosis while also navigating a career, and explaining how her product, which is now FDA-approved, can help patients with cancer and survivors improve their sexual quality of life.

In 2018, Evofem Biosciences founder and CEO Saundra Pelletier was hard at work developing Phexxi, a non-hormonal contraceptive gel for women. Amid a phase 3 clinical trial evaluating its efficacy, Pelletier - who had been “religious” about health checkups and had just received a clean mammogram the year before - was blindsided by a diagnosis of aggressive, stage 3 breast cancer.

The news was, as she says, "Shocking in a way that is so hard to describe.” Pelletier said she was not even sure how to feel or react. After dealing with her immediate concerns about her son, Pelletier’s worry soon shifted to her ability to stay in her role at Evofem.

But after reassuring discussions with coworkers, she was able to continue to run the company while undergoing treatments including chemotherapy, a double mastectomy, and a hysterectomy. Today, she’s talking with CURE about what it was like to go through the shock of receiving a cancer diagnosis while also navigating a career, and explaining how her product, which is now FDA-approved, can help patients with cancer and survivors improve their sexual quality of life.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
Image of two doctors with text.
Imiage of two doctors with text.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Picture of Dr. Pouneh Razavi
Related Content